TPWA
OCUL icon

Twin Peaks Wealth Advisors’s Ocular Therapeutix OCUL Stock Holding History

Twin Peaks Wealth Advisors’s Portfolio OCUL Stock Details OCUL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-19
Closed -$161 – 1555
2026
Q1 		$161 Buy
+19
New +$181 ﹤0.01% 2201
2025
Q3 		– Sell
-2
Closed -$25 – 1472
2025
Q2 		$25 Buy
+2
New +$16 ﹤0.01% 2238

Other funds holding OCUL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $161M AUM 27.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Twin Peaks Wealth Advisors's OCUL Position: Q2 2026 in Review

Twin Peaks Wealth Advisors sold out of Ocular Therapeutix (OCUL) in Q2 2026, closing a stake of 19 shares — an estimated $161 sold.

Twin Peaks Wealth Advisors first reported a position in OCUL in Q2 2025 and held it in 2 quarters. The position peaked at $161 in Q1 2026. 261 funds tracked by Wall St. Rank hold OCUL as of Q2 2026.

  • Twin Peaks Wealth Advisors reported no remaining Ocular Therapeutix position as of Q2 2026 after selling out during the quarter.
  • Twin Peaks Wealth Advisors sold 19 Ocular Therapeutix shares in Q2 2026, an estimated $161.
  • Twin Peaks Wealth Advisors first reported a position in Ocular Therapeutix in Q2 2025 and held it in 2 quarters.
  • Twin Peaks Wealth Advisors's Ocular Therapeutix position peaked at $161 in Q1 2026.
  • 261 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2026.

Based on Twin Peaks Wealth Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.